Loading
A phase 1/2 trial of Zanubrutinib in diffuse large B-cell lymphoma, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL is a phase 1/2 interventional study registered as NCT06375733 by Genfleet Therapeutics (Shanghai) Inc., with 51 participants planned, started 2024-03-20 and due to reach its primary completion in 2026-12-31. Interventions recorded: GFH009 and Zanubrutinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares Zanubrutinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares Zanubrutinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares Zanubrutinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/